{"id":"dalteparin-injectable-solution","safety":{"commonSideEffects":[{"rate":"1-5%","effect":"Bleeding"},{"rate":"<1%","effect":"Thrombocytopenia"},{"rate":"1-3%","effect":"Injection site hematoma"},{"rate":"<1%","effect":"Elevated transaminases"},{"rate":null,"effect":"Osteoporosis (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL1201460","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated factor X (Xa) and thrombin (factor IIa). This prevents the formation and extension of fibrin clots. Low-molecular-weight heparins like dalteparin have more predictable pharmacokinetics and longer half-lives than unfractionated heparin, allowing for subcutaneous dosing.","oneSentence":"Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:39.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Venous thromboembolism prophylaxis"},{"name":"Treatment of deep vein thrombosis"},{"name":"Treatment of pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT05569681","phase":"NA","title":"Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients","status":"RECRUITING","sponsor":"Hawler Medical University","startDate":"2023-01-07","conditions":"Morbid Obesity","enrollment":2400},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT01588171","phase":"NA","title":"Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2012-05","conditions":"Venous Thromboembolic Diseases","enrollment":7020},{"nctId":"NCT07116239","phase":"NA","title":"Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-09","conditions":"Nephrotic Syndrome, Hypoalbuminemia","enrollment":60},{"nctId":"NCT07087366","phase":"NA","title":"Enhanced Recovery After Surgery(ERAS) Following Gynaecological Oncology Surgery in a Tertiary Level Hospital","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-06-01","conditions":"ERAS, Cancer","enrollment":130},{"nctId":"NCT06712004","phase":"PHASE2","title":"A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-02-10","conditions":"Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction","enrollment":40},{"nctId":"NCT05284552","phase":"PHASE2","title":"Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","status":"RECRUITING","sponsor":"University Hospital, Linkoeping","startDate":"2022-07-12","conditions":"Epithelial Ovarian Cancer","enrollment":40},{"nctId":"NCT01130025","phase":"PHASE3","title":"Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2010-08","conditions":"Venous Thromboembolism","enrollment":900},{"nctId":"NCT06693362","phase":"PHASE1","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-20","conditions":"Severe Viral Pneumonia(Not Include COVID-19)","enrollment":60},{"nctId":"NCT04427098","phase":"PHASE2","title":"Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2020-05-22","conditions":"COVID-19","enrollment":301},{"nctId":"NCT04088292","phase":"PHASE3","title":"Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2019-06-06","conditions":"Pulmonary Embolism","enrollment":210},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT01630148","phase":"NA","title":"Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2012-07","conditions":"Deep Vein Thrombosis (DVT), Pulmonary Embolism","enrollment":774},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06049758","phase":"NA","title":"D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy","status":"NOT_YET_RECRUITING","sponsor":"General Committee of Teaching Hospitals and Institutes, Egypt","startDate":"2024-01-02","conditions":"Blood Loss, Intensive Care, Anastomotic Leakage","enrollment":80},{"nctId":"NCT02607319","phase":"PHASE4","title":"Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","startDate":"2015-11","conditions":"Sterility","enrollment":165},{"nctId":"NCT05265676","phase":"PHASE1","title":"Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects","status":"COMPLETED","sponsor":"Venus Remedies Limited","startDate":"2021-02-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT00633061","phase":"PHASE2","title":"Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2008-06","conditions":"Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis","enrollment":136},{"nctId":"NCT04235569","phase":"PHASE4","title":"Warfarin Initiation in Mechanical Mitral Valve Replacement Patients","status":"COMPLETED","sponsor":"Sarah Sabry Hashem","startDate":"2018-03-01","conditions":"Mitral Valve Disease","enrollment":50},{"nctId":"NCT02073682","phase":"PHASE3","title":"Cancer Venous Thromboembolism (VTE)","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-07-16","conditions":"Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)","enrollment":1046},{"nctId":"NCT03601338","phase":"EARLY_PHASE1","title":"Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths","status":"COMPLETED","sponsor":"Hawler Medical University","startDate":"2015-08-01","conditions":"Unexplained Stillbirth","enrollment":140},{"nctId":"NCT03591471","phase":"PHASE1, PHASE2","title":"Study on Children Henoch-Schönlein Purpura Nephritis With TCM Multistep Treatment","status":"UNKNOWN","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2014-09","conditions":"Henoch-Schönlein Purpura Nephritis","enrollment":500},{"nctId":"NCT02411331","phase":"NA","title":"Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci","status":"UNKNOWN","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2015-03","conditions":"Lock Solution, Catheter Related Blood Stream Infections, Central Venous Catheter Infection","enrollment":180},{"nctId":"NCT00311090","phase":"PHASE3","title":"Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-04","conditions":"Deep Venous Thrombosis","enrollment":757},{"nctId":"NCT00345618","phase":"PHASE3","title":"Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Embolism, Thrombosis","enrollment":3202},{"nctId":"NCT00986765","phase":"PHASE3","title":"Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-06","conditions":"Preeclampsia","enrollment":257},{"nctId":"NCT01356992","phase":"PHASE3","title":"Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation","status":"TERMINATED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-07","conditions":"Non ST Segment Elevation Myocardial Infarction, Unstable Angina","enrollment":62},{"nctId":"NCT02379663","phase":"PHASE4","title":"Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-01","conditions":"Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures","enrollment":639},{"nctId":"NCT00679588","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-04","conditions":"Venous Thromboembolism","enrollment":4413},{"nctId":"NCT00721760","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":1003},{"nctId":"NCT00697099","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-06","conditions":"Venous Thromboembolism","enrollment":2326},{"nctId":"NCT00718224","phase":"PHASE3","title":"Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":1150},{"nctId":"NCT00714597","phase":"PHASE3","title":"Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-07","conditions":"Venous Thromboembolism","enrollment":421},{"nctId":"NCT00331838","phase":"PHASE2","title":"Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Venous Thromboembolism","enrollment":705},{"nctId":"NCT00951574","phase":"PHASE3","title":"Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2003-10","conditions":"Advanced Cancer, Metastatic Cancer","enrollment":1166}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dalteparin Injectable Solution","genericName":"Dalteparin Injectable Solution","companyName":"Queen Mary University of London","companyId":"queen-mary-university-of-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis, Treatment of deep vein thrombosis, Treatment of pulmonary embolism.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}